David F. McDermott

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.646Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Papers

Driven by 46 papers — median percentile 46. Top paper: “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial”.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

Frontiers in Oncology(2020)10.3389/fonc.2019.01483

N/A

0.865DataRank · unranked

12 citations

Howard L. Kaufman, Brendan D. Curti, Janice M. Mehnert, Kim Margolin, David F. McDermott +10 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9522

N/A

0.326DataRank · unranked

3 citations

Donald P. Lawrence, David F. McDermott, Mofei Liu, Elizabeth I. Buchbinder, Irena Gushterova +14 more

A Foundation Model for Spatial Proteomics

arXiv (Cornell University)(2025)10.48550/arxiv.2506.03373

N/A

0.292DataRank · unranked

6 citations

Yuzhou Chang, Huaying Qiu, Yao Yu Yeo, Guillaume Jaume, Yuchen Wang +55 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16521

Top 65%

0.198DataRank

Top 65%2 citations

Maheetha Bharadwaj, Grace Birch, Nicholas Schindler, Chris Labaki, Renée Maria Saliby +13 more

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003743

N/A

0DataRank · unranked

36 citations

Charlene Mantia, Lillian Werner, Ahmad A. Tarhini, James Larkin, F. Stephen Hodi +10 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4596

N/A

0DataRank · unranked

10 citations

Se Eun Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella +15 more

Integrative clinical and molecular characterization of translocation renal cell carcinoma

Cell Reports(2022)10.1016/j.celrep.2021.110190

N/A

0DataRank · unranked

118 citations

Ananthan Sadagopan, Praful Ravi, Nebiyou Y. Metaferia, Jiao Li, Shatha AbuHammad +35 more

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2274

N/A

0DataRank · unranked

37 citations

Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton +16 more

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.100947

N/A

0DataRank · unranked

27 citations

Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban +10 more

Regulation of HHLA2 expression in kidney cancer and myeloid cells

BMC Cancer(2023)10.1186/s12885-023-11496-9

N/A

0DataRank · unranked

7 citations

Nahuel Perrot, Zimo Huang, Rupal S. Bhatt, Aseman Sheshdeh Bagheri, Nourhan El Ahmar +6 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4541

N/A

0DataRank · unranked

1 citations

Se Eun Kim, David F. McDermott, Viraj A. Master, Sabina Signoretti, Mahmut Akgül +13 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2023)10.1158/2326-6066.c.6550380

N/A

0DataRank · unranked

0 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2023)10.1158/2326-6066.c.6550380.v1

N/A

0DataRank · unranked

0 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2023)10.1158/2326-6066.22537789

N/A

0DataRank · unranked

0 citations

Donald P. Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada +18 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

Journal of Clinical Oncology(2024)10.1200/jco.23.00699

N/A

0DataRank · unranked

25 citations

Valérie Gaborieau, Samuel M. Niman, Anush Mukeria, Xiaowen Liu, Krishna P. Maremanda +14 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial

Journal of Clinical Oncology(2024)10.1200/jco.24.00279

N/A

0DataRank · unranked

16 citations

Meredith M. Regan, Julia S. Stevens, David F. McDermott, Ravi A. Madan, David J. Einstein

Reply to B. Tombal et al

Journal of Clinical Oncology(2024)10.1200/jco-24-01595

N/A

0DataRank · unranked

0 citations

Meredith M. Regan, Julia S. Stevens, David F. McDermott, Ravi A. Madan, David J. Einstein

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

KIM-1 as a Prognostic Marker in Renal Cell Carcinoma

European Urology Focus(2025)10.1016/j.euf.2025.06.012

N/A

0DataRank · unranked

10 citations

Marc Machaalani, Joseph V. Bonventre, David F. McDermott, Toni K. Choueiri, Wenxin Xu +1 more

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.437

N/A

0DataRank · unranked

13 citations

Sai Vikram Vemula, Robert J. Motzer, Aparna Chhibber, Deepthi Chowbene, Nahuel Perrot +7 more

Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.4546

N/A

0DataRank · unranked

0 citations

Renée Maria Saliby, Eddy Saad, Clara Steiner, Caiwei Zhong, Emre Yekedüz +15 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

Cancer Immunology Research(2020)10.1158/2326-6066.cir-20-0315

N/A

0DataRank · unranked

113 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Radiology(2020)10.1148/radiol.2020201763

N/A

0DataRank · unranked

16 citations

Rupal S. Bhatt, Meaghan F. Strob, Opeyemi A. Jegede, Maryellen Sun, David C. Alsop +6 more

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5023

N/A

0DataRank · unranked

12 citations

Opeyemi A. Jegede, Miriam Sant’Angelo, Sonia Moreno, David A. Braun, Megan Wind‐Rotolo +15 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.28.121806

N/A

0DataRank · unranked

3 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +47 more

Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5010

N/A

0DataRank · unranked

2 citations

Yue Hou, Ziad Bakouny, Miriam Ficial, Miriam Sant’Angelo, Petra Ross‐Macdonald +15 more

Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.746

N/A

0DataRank · unranked

1 citations

Petra Ross‐Macdonald, Sachet A. Shukla, David A. Braun, Linan Song, Eliseo Veras +7 more

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.013

N/A

0DataRank · unranked

525 citations

Kelly Street, Kelly P. Burke, David L. Cookmeyer, Thomas Denize, Christina B. Pedersen +30 more

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Nature Communications(2021)10.1038/s41467-021-21068-9

N/A

0DataRank · unranked

169 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +48 more

David F. McDermott

Indexed papers

Top data-sharing exemplar

Papers